

BRA-24KIT、BRA-48KIT 使用論文

- 1) Kim JL, Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts. *J Cell Biochem.* 2012, 113(1):247-59.
- 2) Kuo CH, Lung tumor associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway. *Carcinogenesis.* 2013, 34(11):2600-9.
- 3) Tanaka H, Nicotine affects bone resorption and suppresses the expression of cathepsin K, MMP-9 and vacuolar-type H(+)-ATPase d2 and actin organization in osteoclasts. *PLoS One.* 2013, 8(3):e59402.
- 4) Kang JH, Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis. *J Dent Res.* 2014, 93(11):1116-23.
- 5) Nishida H, Blockade of CD26 signaling inhibits human osteoclast development. *J Bone Miner Res.* 2014, 29(11):2439-55.
- 6) Kloos B, Pasteurella multocida toxin- induced osteoclastogenesis requires mTOR activation. *Cell Commun Signal.* 2015, 13:40.
- 7) Sapkota M, Bromo-honauicin A inhibits osteoclastogenic differentiation in RAW 264.7 cells via Akt and ERK signaling pathways. *Eur J Pharmacol.* 2015, 769:100-9.
- 8) Choe CH, Transmembrane protein 173 inhibits RANKL-induced osteoclast differentiation. *FEBS Lett.* 2015, 589(7):836-41.
- 9) Li L, Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. *Eur J Pharmacol.* 2016, 777:17-25.
- 10) Cheng TL, Myeloid thrombomodulin lectin-like domain inhibits osteoclastogenesis and inflammatory bone loss. *Sci Rep.* 2016, 17:6:28340.
- 11) Shiota J, Igaratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factor

of Activated T Cells Signaling Pathway. *Open Journal of Rheumatology and Autoimmune Diseases*, 2016, 6, 106-119

- 12) Joung YH, Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF- κ B and STAT3 Activities. *PLoS One*. 2016, 22;11(7):e0159891.
- 13) Qiu ZC, Discovery of a New Class of Cathepsin K Inhibitors in *Rhizoma Drynariae* as Potential Candidates for the Treatment of Osteoporosis. *Int J Mol Sci*. 2016, 17(12):2116.
- 14) Lee SH, Anti-Osteoclastic Activity of *Artemisia capillaris* Thunb. Extract Depends upon Attenuation of Osteoclast Differentiation and Bone Resorption-Associated Acidification Due to Chlorogenic Acid, Hyperoside, and Scoparone. *Int J Mol Sci*. 2017, 18(2) 322.
- 15) Lee DH, Nutrikinetics of Isoflavone Metabolites After Fermented Soybean Product (Cheonggukjang) Ingestion in Ovariectomized Mice. *Mol Nutr Food Res*. 2017, 61(12).
- 16) Funaki Y, Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation. *Yonago Acta Med*. 2018, 61(1):8-18.
- 17) Chu G, Punicagin inhibits RANKL-induced osteoclastogenesis by suppressing NF- κ B and MAPK signaling pathways *Int J Clin Exp Med* 2018;11(7):6571-6582
- 18) Sapkota M, Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice. *Food Chem Toxicol*, 2018, 120:418-429.
- 19) Na S, Dose analysis of photobiomodulation therapy on osteoblast, osteoclast, and osteocyte. *J Biomed Opt*, 2018, 23(7):1-8.
- 20) Kim HY, Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of κ B Kinase and Inflammasome-Mediated Interleukin-1 β Secretion. *Oxid Med Cell Longev*. 2019, 2019:3503912.

- 21) Abdallah BM, The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways. *Biomed Res Int.* 2019, 9395146.
- 22) Steller D, Establishment and validation of an in vitro co-culture model for oral cell lines using human PBMC-derived osteoclasts, osteoblasts, fibroblasts and keratinocytes. *Sci Rep*, 2020, 10(1):16861.
- 23) Chen Z, 2-NPPA Mitigates Osteoclastogenesis via Reducing TRAF6-Mediated c-fos Expression. *Front Pharmacol*, 2021, 11:599081.
- 24) Chen Z, N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) acetamide is a novel inhibitor of resorptive bone loss in mice. *J Cell Mol Med*, 2021, 25(3):1425-1438.
- 25) Watahiki A, Deficiency of Lipin2 Results in Enhanced NF- κ B Signaling and Osteoclast Formation in RAW-D Murine Macrophages. *Int J Mol Sci*, 2021, 22(6):2893.
- 26) Zang L, 10-Gingerol Suppresses Osteoclastogenesis in RAW264.7 Cells and Zebrafish Osteoporotic Scales. *Front Cell Dev Biol*, 2021 9:588093.
- 27) Akashi Y, Cyclic Pressure-Induced Cytokines from Gingival Fibroblasts Stimulate Osteoclast Activity: Clinical Implications for Alveolar Bone Loss in Denture Wearers. *J Prosthodont Res*, 2022.
- 28) Alam MI, NLRP3 Inflammasome Negatively Regulates RANKL-Induced Osteoclastogenesis of Mouse Bone Marrow Macrophages but Positively Regulates It in the Presence of Lipopolysaccharides. *Int J Mol Sci*, 2022, 23(11):6096.
- 29) Mohamad Hazir NS, Changes in Metabolism and Mitochondrial Bioenergetics during Polyethylene-Induced Osteoclastogenesis. *Int J Mol Sci.* 2022, 23(15): 8331.
- 30) Whitlock JM, An inducible explant model for dissecting osteoclast-osteoblast coordination in health and disease. *bioRxiv*, doi: <https://doi.org/10.1101/2022.10.27.514052>